Moreover during 3 and 12 months of bosentan in the present IPAH-patients, the NT-proBNP serum levels, tended to be lowered by 8% and 37% from baseline without reaching statistical significance (p = 0.11). The gene discussed is NPPB; the disease is idiopathic pulmonary arterial hypertension.